# Endocannabinoid System Clinical Research on Psychosis Risk > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-risk-clinical-insights/ > **Published:** 2026-04-23T00:06:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:55:22-04:00 > **Clinical Summary:** Explore cannabis induced psychosis schizophrenia risk and clinical research on psychosis risk for better understanding and monitoring of psychiatric outcomes. --- #### Clinical Takeaway Patients who experience cannabis-induced psychosis have a documented risk of subsequently developing schizophrenia spectrum or [bipolar disorder](https://cedclinic.com/cannabis-induced-appetite-satiety-bypass-thc-brain/), with prevalence varying across studies due to differences in follow-up duration and diagnostic criteria. This distinction matters clinically because early identification and appropriate treatment protocols may influence long-term psychiatric outcomes. Current evidence supports careful monitoring and standardized diagnostic approaches for patients presenting with cannabis-related psychotic symptoms to differentiate them from primary psychiatric conditions. ### #25 Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis. **Citation:** Javed Mohammad Saad et al. *Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.* BMC psychiatry. 2026. PMID: 41664079. **Study type:** Journal Article, Systematic Review, Meta-Analysis  |  **Topic area:** Psychosis  |  **CED Score:** 10 Design: 6 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Abstract:** BACKGROUND: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. METHODS: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. RESULTS: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. CONCLUSIONS: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41664079/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12922385/)[DOI ↗](https://doi.org/10.1186/s12888-025-07382-2) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Psychosis Risk: Clinical Research Guide](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-bipolar-progression-guide/) A comprehensive guide on [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) related to psychosis risk within the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/). [Read the Guide](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-bipolar-progression-guide/) [Cannabis Induced Psychosis: Systematic Review & Meta-Analysis on Schizophrenia Spectrum & Bipolar Disorder](https://cedclinic.com/cannabis-induced-psychosis-prevalence-schizophrenia-bipolar/) Systematic review and meta-analysis exploring the prevalence of schizophrenia and bipolar disorder after cannabis induced psychosis. [Explore the Study](https://cedclinic.com/cannabis-induced-psychosis-prevalence-schizophrenia-bipolar/) [Cannabis-Induced Psychosis & Schizophrenia Risk: Key Research](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Key research findings on the relationship between cannabis-induced psychosis and schizophrenia risk. [Discover Key Research](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20Clinical%20Research%20on%20Psychosis%20Risk&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-schizophrenia-risk-clinical-insights%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-schizophrenia-risk-clinical-insights%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20Clinical%20Research%20on%20Psychosis%20Risk%20https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-schizophrenia-risk-clinical-insights%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).